This broad pathogenic role underscores TL1A’s potential as a therapeutic target in individuals with IBD who develop extraintestinal manifestations or other immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. Here, TNFSF15 is linked to rheumatoid arthritis.